U.S. drugmaker Clovis Oncology (CLVS.O) said on Wednesday it was likely to file for bankruptcy "in the very near term", as the company struggles to sell its cancer drug Rubraca. Sales of Rubraca, Clovis's only approved drug, have been hit in recent years by intensifying competition from rival ovarian cancer treatments, and partly by lower cancer diagnoses during the COVID-related lockdowns.
